Clinical Trial Update: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating a JAK inhibitor given before donor stem cell transplantation in patients with primary or secondary myelofibrosis has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• JAK inhibitor

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2024-03-05